Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Target Price at $40.33

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has received a consensus rating of "Moderate Buy" from the fourteen brokerages that are presently covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $40.33.

A number of analysts recently issued reports on KROS shares. Cantor Fitzgerald cut Keros Therapeutics from an "overweight" rating to a "neutral" rating in a report on Tuesday, January 21st. Scotiabank reduced their price objective on shares of Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating for the company in a research note on Thursday, January 16th. Wedbush reiterated a "neutral" rating and issued a $15.00 target price on shares of Keros Therapeutics in a research note on Tuesday, April 1st. Piper Sandler cut their price target on shares of Keros Therapeutics from $40.00 to $15.00 and set an "overweight" rating for the company in a report on Friday, January 17th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of Keros Therapeutics in a report on Tuesday, April 1st.

Insiders Place Their Bets

In other Keros Therapeutics news, major shareholder Adar1 Capital Management, Llc acquired 934,258 shares of the stock in a transaction dated Wednesday, April 9th. The stock was purchased at an average cost of $10.13 per share, for a total transaction of $9,464,033.54. Following the acquisition, the insider now owns 4,392,737 shares in the company, valued at $44,498,425.81. The trade was a 27.01 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 22.90% of the company's stock.

Institutional Trading of Keros Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its stake in shares of Keros Therapeutics by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company's stock valued at $42,146,000 after acquiring an additional 46,041 shares during the last quarter. SG Americas Securities LLC bought a new stake in Keros Therapeutics in the fourth quarter valued at approximately $388,000. JPMorgan Chase & Co. boosted its stake in shares of Keros Therapeutics by 585.9% during the fourth quarter. JPMorgan Chase & Co. now owns 213,431 shares of the company's stock valued at $3,379,000 after purchasing an additional 182,314 shares during the period. Barclays PLC boosted its stake in shares of Keros Therapeutics by 140.1% during the third quarter. Barclays PLC now owns 60,014 shares of the company's stock valued at $3,484,000 after purchasing an additional 35,022 shares during the period. Finally, Norges Bank bought a new position in shares of Keros Therapeutics in the fourth quarter worth approximately $1,027,000. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Price Performance

Shares of KROS traded down $0.21 during trading hours on Tuesday, hitting $14.21. The company's stock had a trading volume of 1,003,205 shares, compared to its average volume of 801,264. The business has a 50 day simple moving average of $11.56 and a two-hundred day simple moving average of $27.45. Keros Therapeutics has a 52-week low of $9.12 and a 52-week high of $72.37. The company has a market cap of $576.39 million, a price-to-earnings ratio of -2.73 and a beta of 1.39.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported ($1.14) earnings per share for the quarter, beating analysts' consensus estimates of ($1.36) by $0.22. The business had revenue of $3.04 million during the quarter, compared to analyst estimates of $37.32 million. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Research analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.